Search
29 studies match these filters. Showing 1–25 of 29 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT05685433 | A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE) A prospective, multicenter, single-arm study to evaluate the safety and effectiveness of the eCoin® implanted tibial nerve stimulator in subjects with urgency urinary incontinence (UUI). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 22 sites in total · contact listed | Recruiting | Not applicable | 200target | 22 / 1 | 2023 | Jan 28, 2026 | |
| NCT07209397 | Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication. This study will include women ages 22 to 80 who have had OAB symptoms for… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 9 sites in total · contact listed | Recruiting | Not applicable | 202target | 9 / 1 | 2025 | Jan 30, 2026 | |
| NCT07220083 | A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS. Participants are put into 2 groups randomly, which means by ch… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 307 sites in total · contact listed | Recruiting | Phase 3 | 286target | 307 / 40 | 2026 | Sep 17, 2026 | |
| NCT06942949 | Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial The purpose of this study is to evaluate the safety and performance of the ELS to treat urinary stones. The ELS is intended to break urinary stones into small fragments that can pass during or after the procedure with less or no discomfort. Eligible patients are male or females, age 21 or older, wit… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 20 sites in total · contact listed | Recruiting | Not applicable | 101target | 20 / 1 | 2025 | Jun 16, 2026 | |
| NCT05268289 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 103 sites in total · contact listed | Recruiting | Phase 2 | 240target | 103 / 20 | 2022 | Jul 30, 2026 | |
| NCT06531824 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). Pe… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 557 sites in total · contact listed | Recruiting | Phase 3 | 11,000target | 557 / 20 | 2024 | Sep 17, 2026 | |
| NCT06190717 | Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 21 sites in total · contact listed | Recruiting | Not applicable | 304target | 21 / 1 | 2024 | Apr 13, 2026 | |
| NCT06742723 | A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 771 sites in total | Recruiting | Phase 3 | 5,000target | 771 / 42 | 2025 | Aug 26, 2026 | |
| NCT06567743 | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 80 sites in total · contact listed | Recruiting | Phase 2 | 325target | 80 / 2 | 2024 | Sep 3, 2026 | |
| NCT06510374 | Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC) ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 107 sites in total | Recruiting | Phase 3 | 454target | 107 / 9 | 2024 | Sep 4, 2026 | |
| NCT05485961 | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) out… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 557 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 3,110target | 557 / 35 | 2022 | Aug 11, 2026 | |
| NCT06319820 | A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 193 sites in total | Recruiting | Phase 3 | 641target | 193 / 20 | 2024 | Aug 28, 2026 | |
| NCT06307652 | Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to evaluate the effect of balcinrenone/dapagliflozin vs dapag… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 852 sites in total | Recruiting | Phase 3 | 3,850target | 852 / 39 | 2024 | Sep 11, 2026 | |
| NCT07206056 | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 35 sites in total · contact listed | Recruiting | Phase 1 / Phase 2 | 188target | 35 / 14 | 2025 | Sep 18, 2026 | |
| NCT06533644 | A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 23 sites in total | Recruiting | Phase 2 | 91target | 23 / 1 | 2025 | Jun 23, 2026 | |
| NCT06056830 | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 34 sites in total · contact listed | Recruiting | Phase 3 | 383target | 34 / 3 | 2023 | Sep 11, 2026 | |
| NCT07225946 | A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxe… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 152 sites in total | Recruiting | Phase 3 | 800target | 152 / 17 | 2025 | Aug 28, 2026 | |
| NCT05946213 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a pa… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 413 sites in total | Recruiting | Phase 3 | 1,209target | 413 / 4 | 2023 | Sep 10, 2026 | |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blo… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 581 sites in total | Recruiting | Phase 2 | 314target | 581 / 2 | 2019 | Sep 16, 2026 | |
| NCT04729114 | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their canc… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 25 sites in total | Recruiting | Phase 1 | 174target | 25 / 2 | 2021 | Feb 4, 2026 | |
| NCT06545955 | A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firaden… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 76 sites in total | Recruiting | Phase 3 | 250target | 76 / 7 | 2024 | Aug 6, 2026 | |
| NCT07097142 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine or mitomycin and 5-fluorouracil for the treatment of patients… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 211 sites in total · contact listed | Recruiting | Phase 3 | 486target | 211 / 1 | 2025 | Aug 18, 2026 | |
| NCT07190300 | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 31 sites in total · contact listed | Recruiting | Phase 1 / Phase 2 | 181target | 31 / 14 | 2026 | Jun 23, 2026 | |
| NCT05677100 | Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 50 sites in total | Recruiting | Not applicable | 320target | 50 / 2 | 2023 | Aug 25, 2026 | |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 279 sites in total · contact listed | Recruiting | 75,000target | 279 / 6 | 2015 | Aug 25, 2026 |